Ultragenyx Pharmaceutical (RARE) Times Interest Earned (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Times Interest Earned of -$8.05 for Q1 2026, up 21.21% year-over-year from -$6.64 in Q1 2025, and down 38.31% quarter-over-quarter from -$5.82 in Q4 2025.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) Times Interest Earned (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Times Interest Earned for 14 consecutive years, with -$8.05 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned rose 21.21% year-over-year to -$8.05; the TTM figure through Mar 2026 stood at -$8.17 (up 2.71% YoY), while the FY2025 annual figure was -$8.63, down 1.42% from the prior year.
- Times Interest Earned declined to -$8.05 in Q1 2026 per RARE's latest filing, from -$5.82 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$5.82 in Q4 2025 and bottomed at -$20.75 in Q1 2022.
- Historically, Times Interest Earned has averaged -$10.33 across 5 years, with a median of -$9.17 in 2022.
- On a YoY basis, Times Interest Earned climbed as much as 65.97% in 2022 and fell as far as 81.25% in 2022.
- Ultragenyx Pharmaceutical's Times Interest Earned stood at -$9.17 in 2022, then grew by 23.34% to -$7.03 in 2023, then dropped by 12.33% to -$7.9 in 2024, then gained by 26.35% to -$5.82 in 2025, then sank by 38.31% to -$8.05 in 2026.
- Business Quant data shows RARE's Times Interest Earned at -$8.05 in Q1 2026, -$5.82 in Q4 2025, and -$12.08 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Ultragenyx Pharmaceutical | 1.56 Bn | 1.27 Bn | 180.00 Mn | -3.41 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.41 |
| Mar 31, 2026 | -8.05 |
| Dec 31, 2025 | -5.82 |
| Sep 30, 2025 | -12.08 |
| Jun 30, 2025 | -7.71 |
| Mar 31, 2025 | -10.21 |
| Dec 31, 2024 | -7.90 |
| Sep 30, 2024 | -8.40 |
| Jun 30, 2024 | -7.29 |
| Mar 31, 2024 | -10.43 |
| Dec 31, 2023 | -7.03 |
| Sep 30, 2023 | -8.21 |
| Jun 30, 2023 | -9.62 |
| Mar 31, 2023 | -9.86 |
| Dec 31, 2022 | -9.17 |
| Sep 30, 2022 | -15.52 |
| Jun 30, 2022 | -23.40 |
| Mar 31, 2022 | -20.75 |
| Dec 31, 2021 | -26.96 |
| Sep 30, 2021 | -10.35 |